19:14 , Mar 14, 2019 |  BC Innovations  |  Emerging Company Profile

Silverback: Taking on tumoral myeloid cells

Silverback’s antibody-based conjugates stimulate innate and adaptive immunity by turning myeloid cells against tumors, while overcoming resistance to checkpoint inhibitors and other T cell-targeting immunotherapies. “When you are able to appropriately and potently activate myeloid...
18:09 , Dec 5, 2018 |  BC Innovations  |  Translation in Brief

Engaging with exosomes

A University of Southern California team has developed synthetic exosomes that express multiple multivalent antibodies, giving them a function like T cell bispecific antibodies, but potentially higher avidity. In a paper published in November in...
18:26 , Nov 7, 2018 |  BioCentury  |  Emerging Company Profile

ABL bispecifics

Korean biotech ABL Bio Inc. is developing bispecifics for cancer and Parkinson’s disease, and has evidence suggesting its lead candidate against VEGF and DLL4 is more potent than at least one of its Western competitors....
20:38 , May 17, 2018 |  BC Innovations  |  Emerging Company Profile

Beyond B cells

PureTech Health plc subsidiary Vor Biopharma Inc. plans to combine CAR T therapies with hematopoietic stem cells modified to go unrecognized by CAR Ts. The approach could increase the types of immune cells that can...
19:41 , Apr 12, 2018 |  BC Innovations  |  Translation in Brief

Shape recognition

A Cardiff University team has engineered a D-peptide that mimicked the T cell agonist activity of an influenza peptide and protected mice from infection by the virus. The findings suggest oral vaccines based on synthetic...
18:36 , Jan 11, 2018 |  BC Innovations  |  Emerging Company Profile

Next, after T cells

PD-1 pioneer Lieping Chen is solving some of the unanswered questions from that breakthrough with his new company, NextCure Inc. The idea is to use myeloid cell factors to boost the effectiveness of other T...
22:57 , Nov 14, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: T cell lymphoma; leukemia Patient sample and mouse studies suggest chimeric antigen receptor (CAR) T cells targeting TRBC1 could help treat TRBC1-positive T cell lymphomas and T cell leukemias. In cultures of T cells...
21:55 , Oct 26, 2017 |  BC Innovations  |  Translation in Brief

Transient nanotargeting

A team from the Fred Hutchinson Cancer Research Center has designed nanoparticles that introduce mRNA cargo to therapeutic cells in vitro , without requiring special instrumentation or causing the cell depletion or cytotoxicity that limits...
16:41 , Jun 14, 2017 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Tissue markers The number of tissue-resident memory T cells could help predict responses to therapeutic vaccines in lung cancer patients. In 96 patients, low numbers of intratumoral tissue-resident memory T cells correlated with poor...
23:07 , May 18, 2017 |  BC Innovations  |  Product R&D

Making cells compute

With efficiency in DNA engineering continuing to grow, and an increasing convergence between engineering and biology, synthetic biology -- in its “truest” form -- is coming within striking distance of translating preclinical proof of concept...